Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 5/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.32 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128890 | 0.93 | — | — | |
| SCHEMBL949579 | 0.75 | ALDH1A1 (0.33) | SMPD1ALDH1A1LMNA | |
| SCHEMBL1712690 | 0.72 | TBXAS1 (0.41) | TBXAS1PTGS1PTGS2LMNA | |
| SCHEMBL1712283 | 0.69 | EGLN3 (0.39) | TBXAS1PTGS1PTGS2ALDH1A1LMNA | |
| SCHEMBL2333919 | 0.68 | SLC9A1 (0.36) | TBXAS1KDRSMPD1TLR8SLC9A1 | |
| SCHEMBL20588490 | 0.67 | SLC9A1 (0.38) | TBXAS1KDRSMPD1PTGS1PTGS2 | |
| SCHEMBL45207 | 0.67 | TLR8 (0.44) | TBXAS1TLR8NPC1ALDH1A1LMNA | |
| SCHEMBL8661566 | 0.65 | EGLN3 (0.47) | TBXAS1TLR8ALDH1A1LMNA | |
| SCHEMBL6114927 | 0.65 | TBXAS1 (0.47) | TBXAS1KDRTLR8NPC1LMNA | |
| SCHEMBL6114716 | 0.65 | TBXAS1 (0.47) | TBXAS1KDRTLR8NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0649410-B1 | ANILIDE DERIVATIVES | GLAXO LAB SA (FR) | 1997-05-02 | — | — | EP | claimed |
| EP-0649410-A1 | ANILIDE DERIVATIVES. | GLAXO LAB SA (FR) | 1995-04-26 | — | — | EP | claimed |
| WO-1994001408-A1 | ANILIDE DERIVATIVES | LABORATOIRES GLAXO S.A. (FR) | 1994-01-20 | — | — | WO | claimed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8598162-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-12-03 | — | — | US | disclosed |
| CN-102850336-A | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMA CO LTD | 2013-01-02 | — | — | CN | disclosed |
| CN-102702182-A | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMA CO LTD | 2012-10-03 | — | — | CN | disclosed |
| CN-102558140-A | Derivatives of 4-piperazin-1-1-yl-4-benzo [b] thiophene suitable for the treatment of cns disorders | OTSUKA PHARMA CO LTD | 2012-07-11 | — | — | CN | disclosed |
| EP-2287161-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-2287162-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| CN-101258147-B | 4-piperazin-1-yl-4-benzo [ B ] thiophene derivatives for the treatment of CNS disorders | OTSUKA PHARMA CO LTD | 2012-03-21 | — | — | CN | disclosed |
| EP-1919907-A2 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-5663179-A | CAN SENSITIZE MULTIDRUG RESISTANT CANCER CELLS TO CHEMOTHERAPEUTIC AGENTS | LABORATOIRES GLAXO SA (FR) | 1997-09-02 | — | — | US | disclosed |
| EP-0649410-B1 | ANILIDE DERIVATIVES | GLAXO LAB SA (FR) | 1997-05-02 | — | — | EP | disclosed |
| EP-0649410-B1 | ANILIDE DERIVATIVES | GLAXO LAB SA (FR) | 1997-05-02 | — | — | EP | disclosed |
| EP-0649410-A1 | ANILIDE DERIVATIVES. | GLAXO LAB SA (FR) | 1995-04-26 | — | — | EP | disclosed |
| EP-0649410-A1 | ANILIDE DERIVATIVES. | GLAXO LAB SA (FR) | 1995-04-26 | — | — | EP | disclosed |
| WO-1994001408-A1 | ANILIDE DERIVATIVES | LABORATOIRES GLAXO S.A. (FR) | 1994-01-20 | — | — | WO | disclosed |
| WO-1994001408-A1 | ANILIDE DERIVATIVES | LABORATOIRES GLAXO S.A. (FR) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | TBXAS1 2435/4885KDR 4450/4885SMPD1 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.